174 related articles for article (PubMed ID: 31162838)
41. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
[TBL] [Abstract][Full Text] [Related]
42. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy.
Zelnak AB; Nikolinakos P; Srinivasiah J; Jonas W; Pippas A; Liu Y; Li X; Torres M; O'Regan RM;
Clin Breast Cancer; 2015 Feb; 15(1):31-6. PubMed ID: 25065563
[TBL] [Abstract][Full Text] [Related]
43. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.
Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z
Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830
[TBL] [Abstract][Full Text] [Related]
44. The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
Stover DG; Coloff JL; Barry WT; Brugge JS; Winer EP; Selfors LM
Clin Cancer Res; 2016 Dec; 22(24):6039-6050. PubMed ID: 27330058
[TBL] [Abstract][Full Text] [Related]
45. Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer.
Bao J; Borja N; Rao M; Huth J; Leitch AM; Rivers A; Wooldridge R; Rao R
Cancer Med; 2015 Apr; 4(4):500-6. PubMed ID: 25641925
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
47. Clinical implications of the intrinsic molecular subtypes of breast cancer.
Prat A; Pineda E; Adamo B; Galván P; Fernández A; Gaba L; Díez M; Viladot M; Arance A; Muñoz M
Breast; 2015 Nov; 24 Suppl 2():S26-35. PubMed ID: 26253814
[TBL] [Abstract][Full Text] [Related]
48. Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.
Liu S; Chapman JA; Burnell MJ; Levine MN; Pritchard KI; Whelan TJ; Rugo HS; Albain KS; Perez EA; Virk S; Barry G; Gao D; O'Brien P; Shepherd LE; Nielsen TO; Gelmon KA
Breast Cancer Res Treat; 2015 Jan; 149(2):439-48. PubMed ID: 25552364
[TBL] [Abstract][Full Text] [Related]
49. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Llombart-Cussac A; Bermejo B; Villanueva C; Delaloge S; Morales S; Balmaña J; Amillano K; Bonnefoi H; Casas A; Manso L; Roché H; Gonzalez-Santiago S; Gavilá J; Sánchez-Rovira P; Di Cosimo S; Harbeck N; Charpentier E; Garcia-Ribas I; Radosevic-Robin N; Aura C; Baselga J
Breast Cancer Res Treat; 2015 Nov; 154(2):351-7. PubMed ID: 26536871
[TBL] [Abstract][Full Text] [Related]
50. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of nab-paclitaxel 125 mg/m
Furlanetto J; Jackisch C; Untch M; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Costa SD; Gerber B; Nekljudova V; Loibl S; von Minckwitz G
Breast Cancer Res Treat; 2017 Jun; 163(3):495-506. PubMed ID: 28315068
[TBL] [Abstract][Full Text] [Related]
52. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
53. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
54. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
[TBL] [Abstract][Full Text] [Related]
56. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
[TBL] [Abstract][Full Text] [Related]
57. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response.
Elnemr GM; El-Rashidy AH; Osman AH; Issa LF; Abbas OA; Al-Zahrani AS; El-Seman SM; Mohammed AA; Hassan AA
Asian Pac J Cancer Prev; 2016; 17(2):807-13. PubMed ID: 26925684
[TBL] [Abstract][Full Text] [Related]
58. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG; Jeruss JS; Hughes E; Siziopikou K; Timms KM; Gutin A; Abkevich V; Sangale Z; Solimeno C; Brown KL; Jones J; Hartman AR; Meservey C; Jovanovic B; Helenowski I; Khan SA; Bethke K; Hansen N; Uthe R; Giordano S; Rosen S; Hoskins K; Von Roenn J; Jain S; Parini V; Gradishar W
Breast Cancer Res Treat; 2015 Jun; 151(3):629-38. PubMed ID: 26006067
[TBL] [Abstract][Full Text] [Related]
59. SIRT5 as a biomarker for response to anthracycline-taxane-based neoadjuvant chemotherapy in triple-negative breast cancer.
Xu L; Che X; Wu Y; Song N; Shi S; Wang S; Li C; Zhang L; Zhang X; Qu X; Teng Y
Oncol Rep; 2018 May; 39(5):2315-2323. PubMed ID: 29565454
[TBL] [Abstract][Full Text] [Related]
60. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
